← All trials
NCT03591653
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2018
- Primary completion
- Nov 5, 2019
- Completion date
- Apr 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 290
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.Lead sponsor
- Changhai HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.